News und Analysen

If you're looking for the company-specific headline that sent shares of Viking Therapeutics (NASDAQ: VKTX) soaring today, don't bother. You won't find one. Rather, investors are proverbially

Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and

On February 17, 2026, Commodore Capital disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold all 2,338,287 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth

The weight loss drug market has been one key focus for investors in recent years. This is because demand has been incredibly high, driving blockbuster revenue for companies making such products --

Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like

Over the past year, Merck's (NYSE: MRK) shares have climbed by 46%. That seems a bit surprising. Last year, the company's financial results were relatively weak as it faced declining revenue for one

Novartis (NYSE: NVS) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on

If you're at all interested in the pharmaceutical sector, you may be overwhelmed by the opportunity for GLP-1 weight-loss therapies. Sure, that's an important new drug category, but it isn't the

The bull case for any stock often rests on several aspects of the business. That certainly applies to Medtronic (NYSE: MDT), a healthcare leader. Bulls could point to many reasons the stock is worth

The terms "dividend" and "healthcare stock" usually aren't mentioned in the same sentence. They're almost unavoidable together when talking about Medtronic (NYSE: MDT), however. The company is not

Healthcare is one of the most lucrative industries where investors can find world-class businesses to buy and hold. Industry leaders can be unstoppable long-term wealth creators, though there's no

Axsome Therapeutics (NASDAQ: AXSM) isn't one of the more famous or prominent biotech companies, but investors interested in the industry had better get to know this drugmaker. Not only has Axsome

Many stocks in the healthcare sector are up strongly in 2026. But not health insurance giant UnitedHealth Group (NYSE: UNH). The stock is down almost 13% this year, far underperforming both the S&P

Pfizer (NYSE: PFE) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and analyst upside, this defensive giant may

I am not a scientist or a medical doctor, so I'm a bit leery of buying healthcare stocks. I've actually outsourced this task to BlackRock Health Sciences Trust (NYSE: BME), a high-yield closed-end

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo

While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors.

Shares of Vertex, a biotech

Pfizer (NYSE: PFE) is the name behind one of the world's top-selling products: the coronavirus vaccine. It brought in more than $37 billion at its peak in 2022 and helped the company achieve $100

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Investors were snapping up shares of fintech stock Vertex (NASDAQ: VERX) on Thursday. That followed a rather glowing research update from an analyst at a prominent investment bank. With that in its

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.

That's what the analyst community seems to